$739.53
+0.37%McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Chief Executive Officer & Director
Compensation
$5,661,202
Executive Vice President & Chief Financial Officer
Compensation
$2,681,328
Executive Vice President & Chief Human Resources Officer
Compensation
$1,516,918
Executive Vice President & Chief Legal Officer
Compensation
$2,225,612
Executive Vice President & Group President of North American Pharmaceutical Services
Executive Vice President and Chief Strategy & Business Development Officer
Compensation
$1,462,012
Executive Vice President, Chief Information & Technology Officer
Executive Vice President, Chief Information Officer & Chief Technology Officer
Head of Investor Relations
President of The US Pharmaceutical & Specialty Solutions Business
Senior Vice President of Taxes
Senior Vice President, Controller & Chief Accounting Officer
During the last 12 months, insiders have sold $54.27M worth of MCK shares, with no buying activity reported.
0
0.00
7.7K
5.85M
-5.9M
-$5.85M
0
0.00
4.2K
4.03M
-4.0M
-$4.03M
0
0.00
329
283.48K
-283K
-$283K
0
0.00
62.9K
44.11M
-44.1M
-$44.11M
No buying activity
Tyler Brian S.
Director, Officer: Chief Executive Officer
$43.89M
Lau Michele
Officer: Evp And Chief Legal Officer
$5.68M
Rodgers Thomas L
Officer: Evp, Chief Strategy & Bdo
$2.04M
Smith Leann B
Officer: Evp & Chief Hr Officer
$1.51M
Rutledge Napoleon B Jr
Officer: Svp, Controller & Cao
$815K
Strong bearish signal with $54.27M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
MCK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | June 20, 2025 | March 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 21, 2024 | July 31, 2024 | 2024 | |
DEF 14A DEF 14A N/A | June 09, 2023 | June 09, 2023 | ||
DEF 14A DEF 14A 2022 N/A | June 09, 2022 | July 22, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 08, 2021 | July 23, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | June 18, 2020 | July 29, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 21, 2019 | July 31, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | June 15, 2018 | July 25, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | June 16, 2017 | July 26, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | June 17, 2016 | July 27, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.